Results 1 to 10 of about 3,573 (130)

A Case of Primary Intramedullary Infantile Fibrosarcoma With an RBPMS::NTRK3 Fusion and Response to Larotrectinib. [PDF]

Neuropathol Appl Neurobiol
We report a case of primary intramedullary infantile fibrosarcoma (IFS) in a 4‐week‐old infant with rapidly progressive cervical myelopathy. Histology showed a spindle cell tumour with diffuse S100 and pan‐TRK expression. RNA sequencing identified an RBPMS::NTRK3 fusion.
Le Quang M, Tandonnet J, Truffaux N, Vanhersecke L, Delmas J, Durouchoux A, Bochaton D, Tauziède-Espariat A, Chotard G.   +8 more
europepmc   +2 more sources

Larotrectinib in a NTRK-rearranged soft tissue sarcoma in the neoadjuvant setting: A case report

Clinical Case Reports (discontinued), 2021
Patients with soft tissue sarcomas should be assessed for neurotrophic tropomyosin receptor kinase (NTRK) gene fusions as neoadjuvant treatment with larotrectinib may prevent amputation.
Thomas Schubert, Thomas Kirchgesner, Christine Galant   +2 more
exaly   +2 more sources

Corticosteroids for Managing TRK Inhibitor Withdrawal Pain: A Report on Two Cases [PDF]

Current Oncology
Background: Neurotrophin receptor tyrosine kinase (NTRK) fusions are potent oncogenic mutations. Inhibitors such as larotrectinib, entrectinib and repotrectinib are used when cancer cells harbor NTRK1, NTRK2 or NTRK3 fusion.
Nicolas Marcoux, Louis-Philippe Grenier
doaj   +2 more sources

Understanding Postmarketing Requirements and Commitments for CYP3A-Mediated Drug-Drug Interactions: An Analysis of FDA-Approved Drugs From 2015 to 2024. [PDF]

Clin Transl Sci
ABSTRACT Addressing knowledge gaps at drug approval through drug–drug interaction (DDI)‐related postmarketing requirements (PMRs) and commitments (PMCs) is essential for safe and effective use. This analysis reviewed CYP3A‐related PMRs and PMCs, the most evaluated enzyme in postmarketing studies, to characterize their scope.
Yu J, Petrie I, Argon S, Owens K, Ragueneau-Majlessi I.   +4 more
europepmc   +2 more sources

Understanding access to novel high-cost cancer therapies across Canada: a national survey of pediatric oncology providers [PDF]

Frontiers in Pediatrics
IntroductionMany evidence-informed high-cost therapies for childhood cancer, including targeted drugs, proton beam therapy (PBT), and cellular therapy (CT) are not publicly funded in Canada. This study aimed to identify disparities and barriers to access,
Kriti Kumar, Avram Denburg, Celine Cressman, Derek S. Tsang, Derek S. Tsang, Marcel Romanick, Myanca Rodrigues, Myanca Rodrigues, Paul J. Gibson   +8 more
doaj   +2 more sources

Sustained response to larotrectinib in a pediatric patient with recurrent STRN3::NTRK2 fusion-positive pilocytic astrocytoma [PDF]

CNS Oncology
A 7-year-old female with recurrent midline pilocytic astrocytoma harboring a rare STRN3::NTRK2 fusion achieved sustained near-complete radiographic and clinical response to larotrectinib, a selective TRK inhibitor.
Kishore Balasubramanian, Kar-Ming Fung, Rene Y. McNall-Knapp, Karl Balsara   +3 more
doaj   +2 more sources

Extraskeletal osteosarcoma harboring ETV6::NTRK3 fusion treated successfully with larotrectinib: a case study [PDF]

Communications Medicine
Background Extraskeletal osteosarcoma (ESOS) is a rare, aggressive mesenchymal tumor with limited therapeutic options and a poor prognosis due to frequent metastases. Identifying targetable genetic alterations could improve treatment outcomes.
Kristijan Skok, Florian Ochsenhofer, Raphael Gassner, Andreas Leithner, Joanna Szkandera, Christian Viertler, Sonja Hasenschwandtner, Andreas Reichinger, Bernadette Liegl-Atzwanger   +8 more
doaj   +2 more sources

Not all NTRK fusions in mesenchymal neoplasia are driver events: implications on classification and targeted therapy. [PDF]

J Pathol Clin Res
Abstract NTRK fusions drive the pathogenesis of a distinctive group of mesenchymal neoplasms with significant impact on classification and targeted therapy. However, unexpected NTRK fusions have been reported in other sarcoma entities, raising uncertainty over their specificity and clinical management.
Yakoub MA, Sukhadia P, Saoud C, Hameed M, Antonescu CR.   +4 more
europepmc   +2 more sources

Case Report: Novel findings of larotrectinib in children with NTRK-rearranged spindle cell tumor [PDF]

Frontiers in Oncology
Neurotrophic tropomyosin receptor kinase (NTRK)-rearranged spindle cell tumors are often resistant to chemotherapy and radiotherapy. Fortunately, they are sensitive to targeted therapy of tropomyosin receptor kinase (TRK) inhibitors. However, the data on
Linnan Wu, Linnan Wu, Weiji Xie, Weiji Xie, Juan Wang, Juan Wang, Suying Lu, Suying Lu, Yizhuo Zhang, Yizhuo Zhang, Junting Huang, Junting Huang   +11 more
doaj   +2 more sources

Primary Resistance to Larotrectinib in a Patient With Squamous NSCLC With Subclonal NTRK1 Fusion: Case Report

JTO Clinical and Research Reports, 2023
The NTRK genes encode the TRK proteins. NTRK fusions lead to constitutively active, ligand-independent downstream signaling. NTRK fusions are implicated in up to 1% of all solid tumors and 0.2% of NSCLC.
Mary C. Boulanger, MD, Jennifer S. Temel, MD, Mari Mino-Kenudson, MD, Lauren L. Ritterhouse, MD, PhD, Ibiayi Dagogo-Jack, MD   +4 more
doaj   +1 more source